Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy
Advanced Science · 2024
DOI: 10.1002/advs.202309917 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yelee Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea. Hauptthemen laut MEDLINE: PTEN Phosphohydrolase, Nanoparticles, B7-H1 Antigen. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mid-Career Researcher Program, National Research Foundation, Korean government (MSIT).
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) exhibit remarkable mRNA delivery efficiency, yet their majority accumulate in the liver or spleen after injection. Tissue‐specific mRNA delivery can be achieved through modulating LNP properties, such as tuning PEGylation or varying lipid components systematically. In this paper, a streamlined method is used for incorporating tumor‐targeting peptides into the LNPs; the programmed death ligand 1 (PD‐L1) binding peptides are conjugated to PEGylated lipids via a copper‐free click reaction, and directly incorporated into the LNP composition (Pep LNPs). Notably, Pep LNPs display robust interaction with PD‐L1 proteins, which leads to the uptake of LNPs into PD‐L1 overexpressing cancer cells both in vitro and in vivo. To evaluate anticancer immunotherapy mediated by restoring tumor suppressor, mRNA encoding phosphatase and tensin homolog (PTEN) is delivered via Pep LNPs to PTEN‐deficient triple‐negative breast cancers (TNBCs). Pep LNPs loaded with PTEN mRNA specifically promotes autophagy‐mediated immunogenic cell death in 4T1 tumors, resulting in effective anticancer immune responses. This study highlights the potential of tumor‐targeted LNPs for mRNA‐based cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
- Department of Life Sciences, Korea University, Seoul, 02841, Republic of Korea.
- Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
- Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology, Seoul, 02792, Republic of Korea.
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju, 52828, Republic of Korea.
- KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.
ORCID-Profile: Yoosoo Yang
Förderung
- Mid-Career Researcher Program
- National Research Foundation
- Korean government (MSIT)
- Intramural Research Program of the Korea Institute of Science and Technology
- KU-KIST Graduate School of Converging Science and Technology
Zitieren
APA
Kim, Y., Choi, J., Kim, E. H., Park, W., Jang, H., Jang, Y., Chi, S. G., Kweon, D. H., Lee, K., Kim, S. H., & Yang, Y. (2024). Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy. Advanced Science. https://doi.org/10.1002/advs.202309917
Vancouver
Kim Y, Choi J, Kim EH, Park W, Jang H, Jang Y, et al. Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy. Advanced Science. 2024. doi:10.1002/advs.202309917
BibTeX
@article{Kim2024,
author = {Kim, Yelee and Choi, Jiwoong and Kim, Eun Hye and Park, Wonbeom and Jang, Hochung and Jang, Yeongji and Chi, Sung-Gil and Kweon, Dae-Hyuk and Lee, Kyuri and Kim, Sun Hwa and Yang, Yoosoo},
title = {Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202309917}
}
EUVIMED